Standout Papers

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup><i>G12C</i>... 2022 2026 2023 2024186
  1. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1) (2022)
    Sai‐Hong Ignatius Ou, Pasi A. Jänne et al. Journal of Clinical Oncology

Immediate Impact

63 standout
Sub-graph 1 of 22

Citing Papers

Pancreatic cancer
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
1 intermediate paper

Works of Xiaohong Yan being referenced

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
2022 Standout
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
2021

Author Peers

Author Last Decade Papers Cites
Xiaohong Yan 347 222 105 147 48 579
Shuncong Wang 337 203 96 203 38 738
Murat Serilmez 232 197 102 90 34 558
Faruk Taş 231 153 122 97 44 569
Giuseppe Gullo 362 267 149 150 41 677
Maria Melachrinou 163 227 93 127 50 701
Antonella Perotti 309 227 97 140 24 574
Feng Wang 230 262 146 112 51 572
Marianna Silletta 215 153 85 204 39 594
A. Reinacher-Schick 434 170 147 144 46 625
Xinmin Zhao 345 253 134 253 46 640

All Works

Loading papers...

Rankless by CCL
2026